Skip to content

Study · Systematic review · n = 1,405 · 2020

4 results

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.

Lingvay I, Capehorn MS, Catarig AM, Johansen P, Lawson J, Sandberg A, Shaw R, Paine A

The Journal of clinical endocrinology and metabolism1 Dec 2020Cited by 19 (Europe PMC)

PMID32827435 (opens in a new tab)PMCIDPMC7549924 (opens in a new tab)DOI10.1210/clinem/dgaa577 (opens in a new tab)PepBankPUB-32827435
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

ContextNo head-to-head trials have directly compared once-weekly (OW) semaglutide, a human glucagon-like peptide-1 analog, with empagliflozin, a sodium-glucose co-transporter-2 inhibitor, in type 2 diabetes (T2D).ObjectiveWe indirectly compared the efficacy of OW semaglutide 1 mg vs once-daily (OD) empagliflozin 25 mg in patients with T2D inadequately controlled on metformin monotherapy, using individual patient data (IPD) and meta-regression methodology.Design, setting, participants, and interventionsIPD for patients with T2D receiving metformin monotherapy and randomized to OW semaglutide 1 mg (SUSTAIN 2, 3, 8 trials), or to OD empagliflozin 25 mg (PIONEER 2 trial) were included. Meta-regression analyses were adjusted for potential prognostic factors and effect modifiers.Main outcome measuresThe primary efficacy outcomes were change from baseline to end-of-treatment (~1 year) in HbA1c (%-point) and body weight (kg). Responder outcomes and other clinically relevant efficacy measures were analyzed.ResultsBaseline characteristics were similar between OW semaglutide (n = 995) and empagliflozin (n = 410). Our analyses showed that OW semaglutide significantly reduced mean HbA1c and body weight vs empagliflozin (estimated treatment difference: -0.61%-point [95% confidence interval (CI): -0.72; -0.49] and -1.65 kg [95% CI: -2.22; -1.08], respectively; both P < 0.0001). Complementary analyses supported the robustness of these results. A significantly greater proportion of patients on OW semaglutide vs empagliflozin also achieved HbA1c targets and weight-loss responses.ConclusionsThis indirect comparison suggests that OW semaglutide 1 mg provides superior reductions in HbA1c and body weight vs OD empagliflozin 25 mg in patients with T2D when added to metformin monotherapy.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes on metformin, semaglutide 1 mg once weekly reduced HbA1c more than empagliflozin 25 mg once daily in an indirect comparison.

    In plain wordsIn adults with type 2 diabetes on metformin, an indirect comparison found that semaglutide lowered HbA1c more than empagliflozin.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change from baseline to end of treatment
    Study

    n = 1,405

    Comparator
    Empagliflozin 25 mg once daily
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg once weekly · ~1 yearAs given in this study (human).

    Measurements

    HbA1c treatment difference
    −0.61 %-point
    semaglutide vs empagliflozin

    Source sentences

    Summary
    Our analyses showed that OW semaglutide significantly reduced mean HbA1c and body weight vs empagliflozin (estimated treatment difference: -0.61%-point [95% confidence interval (CI): -0.72; -0.49] and -1.65 kg [95% CI: -2.22; -1.08], respectively; both P < 0.0001).
    2 context sentences
    Summary · context
    IPD for patients with T2D receiving metformin monotherapy and randomized to OW semaglutide 1 mg (SUSTAIN 2, 3, 8 trials), or to OD empagliflozin 25 mg (PIONEER 2 trial) were included.
    Summary · context
    Baseline characteristics were similar between OW semaglutide (n = 995) and empagliflozin (n = 410).
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes on metformin, semaglutide 1 mg once weekly reduced body weight more than empagliflozin 25 mg once daily in an indirect comparison.

    In plain wordsIn adults with type 2 diabetes on metformin, an indirect comparison found that semaglutide led to more weight loss than empagliflozin.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change from baseline to end of treatment
    Study

    n = 1,405

    Comparator
    Empagliflozin 25 mg once daily
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1 mg once weekly · ~1 yearAs given in this study (human).

    Measurements

    Body weight treatment difference
    −1.65 kg
    semaglutide vs empagliflozin

    Source sentences

    Summary
    Our analyses showed that OW semaglutide significantly reduced mean HbA1c and body weight vs empagliflozin (estimated treatment difference: -0.61%-point [95% confidence interval (CI): -0.72; -0.49] and -1.65 kg [95% CI: -2.22; -1.08], respectively; both P < 0.0001).
    2 context sentences
    Summary · context
    IPD for patients with T2D receiving metformin monotherapy and randomized to OW semaglutide 1 mg (SUSTAIN 2, 3, 8 trials), or to OD empagliflozin 25 mg (PIONEER 2 trial) were included.
    Summary · context
    Baseline characteristics were similar between OW semaglutide (n = 995) and empagliflozin (n = 410).
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes on metformin, a significantly greater proportion on semaglutide than on empagliflozin achieved HbA1c targets in an indirect comparison.

    In plain wordsIn adults with type 2 diabetes on metformin, an indirect comparison found that more people on semaglutide than on empagliflozin reached HbA1c targets.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion achieving HbA1c targets
    Study

    n = 1,405

    Comparator
    Empagliflozin 25 mg once daily
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg once weekly · ~1 yearAs given in this study (human).

    Source sentences

    Summary
    A significantly greater proportion of patients on OW semaglutide vs empagliflozin also achieved HbA1c targets and weight-loss responses.
    2 context sentences
    Summary · context
    IPD for patients with T2D receiving metformin monotherapy and randomized to OW semaglutide 1 mg (SUSTAIN 2, 3, 8 trials), or to OD empagliflozin 25 mg (PIONEER 2 trial) were included.
    Summary · context
    Baseline characteristics were similar between OW semaglutide (n = 995) and empagliflozin (n = 410).
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes on metformin, a significantly greater proportion on semaglutide than on empagliflozin achieved weight-loss responses in an indirect comparison.

    In plain wordsIn adults with type 2 diabetes on metformin, an indirect comparison found that more people on semaglutide than on empagliflozin reached weight-loss goals.

    Peptide
    Semaglutide
    Outcome
    IncreaseProportion achieving weight-loss responses
    Study

    n = 1,405

    Comparator
    Empagliflozin 25 mg once daily
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1 mg once weekly · ~1 yearAs given in this study (human).

    Source sentences

    Summary
    A significantly greater proportion of patients on OW semaglutide vs empagliflozin also achieved HbA1c targets and weight-loss responses.
    2 context sentences
    Summary · context
    IPD for patients with T2D receiving metformin monotherapy and randomized to OW semaglutide 1 mg (SUSTAIN 2, 3, 8 trials), or to OD empagliflozin 25 mg (PIONEER 2 trial) were included.
    Summary · context
    Baseline characteristics were similar between OW semaglutide (n = 995) and empagliflozin (n = 410).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials4

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

4 trials · 4 completed · 4 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03136484

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 78815 Mar 2017 to 16 Nov 2018

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 21 Jan 2020
CompletedPhase 3Results postedNCT02863328

Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/Sn = 82210 Aug 2016 to 8 Mar 2018

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 20 Jul 2022
CompletedPhase 3Results postedNCT01885208

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 8132 Dec 2013 to 13 Jul 2015

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 13 Jun 2019
CompletedPhase 3Results postedNCT01930188

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 1,2312 Dec 2013 to 12 Oct 2015

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 13 Jun 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.